Use of vancomycin in pediatrics

Pediatric Infectious Disease Journal

Volumn 29, Issue 5, 2010, Pages 462-464

  Dehority, Walter ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Methicillin resistant staphylococci; Vancomycin pediatric dosing; Vancomycin pharmacology

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BONE INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHILD HEALTH CARE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG UTILIZATION; ERYTHEMA; HEARING LOSS; HUMAN; INFECTIOUS ARTHRITIS; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 77951787052     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181db7398     Document Type: Review

References (31)

1. Geraci J, et al. Antibiotic therapy.. VII. Van-comycin for.. endocarditis.. Proc Staff Meet Mayo Clin. 1958;33:172-181.
2. Rybak M. The pharmacokinetic.. properties of vancomcyin. Clin Infect Dis. 2006;42(Suppl 1): S35-S39
3. Bradley JSAntimicrobial agents. In: Long SS, et al, eds. Principles and Practice of Ped Inf Dis. 3rd ed. Philadelphia: Churchill Livingstone; 2008:1420.
4. Cantu TG, et al. Serum vancomycin concentrations.. Clin Inf Dis. 1994;18:533-543.
5. Rybak M, et al. Nephrotoxicity of vancomy-cin.. J Antimicro Chemotherapy. 1990;25:679.
6. Rybak M, et al. Therapeutic monitoring of vanco-mycin.. A consensus review.. Am J Health Syst Pharm. 2009;66:82-98.
7. Farber B, et al. Retrospective study of the toxicity.. vancomycin.. Antimicrob Agents Chemother. 1983;23:138-141.
8. Sorrell TC, Collignon P. A prospective study of adverse reactions.. J Antimicrob Chemother. 1985;16:235-241.
9. Moellering RC Jr. Monitoring serum vancomy-cin.. Clin Infect Dis. 1994;18:544-546.
10. Lodise T, et al. Relationship between initial van-comcyin concentration-time profile.. Clin Infect Dis. 2009;49:507-514.
11. Hammett-Stabler C, Johns T. Laboratory guidelines for monitoring.. Clin Chem. 1998;44: 1129-1140.
12. Baillie G, Neal D. Vancomycin ototoxicity and nephrotoxicity.. Med Toxicol Adverse Drug Exp. 1988;3:376-386.
13. Stier G, et al. Hemodynamic effects of rapid vancomcyin administration.. Anesth Analg. 1990;71:394-399.
14. Szymusiak-Mutnick B. Minimizing the oc-curence of red-man syndrome. Amer J Health Systems Pharm. 1996;53:2098.
15. Healy D, et al. Vancomycin induced histamine release.. Comparison of 1 and 2 hour.. Antimicrol Ag Chemother. 1990;34:550.
16. Ackerman B, et al. Analysis of vancomycin time-kill.. Antimicrob Ag Chemother. 1992;36.
17. Lowdin E, et al. In-vitro studies of.. vancomycin against Staphylococcus.. Antimicrob Ag. 1998; 42:2739-2744.
18. Moise-Broder P, et al. Pharmacodynamics of vancomycin.. Clinl Pharmacokinetics. 2004; 43:925.
19. Moise-Broder P, et al. Area under the inhibitory curve and a pneumonia scoring system for.. vancomcyin therapy.. Amer J Health Systems Pharmacists. 2000;57:S4.
20. Pou L, et al. Changes in vancomycin pharmaco-kinetics during treatment. Ther Drug Monit. 1996;18:149-153.
21. Cruciani M, et al. Penetration of vancomycin.. lung tissue. J Antimicrob Chemother. 1996;38:865.
22. Biavasco F, et al. Glycopeptide resistance in coagulase-negative Staphylococci. Eur J Clinl Microbio Inf Dis. 2000;19:403.
23. Bradley J, et al. Nelson's Pocket Book of Pediat-ric Antimicrobial Therapy. 17th ed. Buenos, Aires: Alliance for Worldwide Editing; 2008.
24. Taketomo C, et al. Pediatric Dosage Handbook. 16th ed. Hudson, OH: Lexi-Comp; 2008.
25. Hoog MD, et al. Vancomycin: Pharmacokinetics and administration regimes in neonates. Clin Pharmacokinetics. 2004;43:417.
26. Charles P, et al. Clinical features associated with bacteremia due to heterogeneous vancomcyin-intermediate Staphylococcus aureus. Clin Inf Dis. 2004;38:448.
27. Sakoulas G, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin.. J Clin Microbio. 2004;42:2398.
28. Sakoulas G, Moellering R. Increasing antibiotic resistance among methicillin-resistant Staphylo-coccus.. Clin Inf Dis. 2008;46:S360.
29. Frymoyer A, et al. Current recommended dosing of vancomycin for children.. Ped Inf Dis J. 2009;28:398.
30. Garrazino S, et al. Glycopeptide bone penetration.. Clin Pharmacokinetics. 2008;47:793.
31. Klugman K, et al. Bactericidal activity against cephalosporin-resistant Streptococcus pneu-moniae.. Antimicrob Ag Chemother. 1995;39: 1988.